Alembic Pharma Vadodara facility concludes USFDA inspection with zero observations

Written by Ruchika Sharma Published On 2022-10-27T13:30:00+05:30 | Updated On 27 Oct 2022 1:30 PM IST

Alembic Pharma Vadodara facility concludes USFDA inspection with zero observations

Vadodara: Alembic Pharma has recently announced that the Company has successfully completed the United States Food and Drug Administration (USFDA) inspection for its Bioequivalence Facility located at Vadodara without any observations.

The inspection was conducted from 17th October 2022 to 21st October 2022.

Alembic Pharmaceuticals Limited is a vertically integrated research and development pharmaceutical company headquartered in Gujarat. It is involved in manufacturing and marketing India Formulations, International Generics, and Active Pharmaceutical Ingredients with vertical integration capabilities. Products under International Generics are manufactured across our world-class facilities in Panelav, Karkhadi, and Jarod in Gujarat. Under this vertical, the company also has R&D facilities in Vadodara (Gujarat), Hyderabad (Telangana), and New Jersey (USA).

alembic pharmaalembic pharma newsUSFDAUSFDA inspectionVadodara facility

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751